First human tests begin for experimental hepatitis d drug
NCT ID NCT06740474
Summary
This early-stage study tested the safety of ABI-6250, a potential treatment for Hepatitis D, in 40 healthy volunteers. Researchers gave participants single and multiple doses to check for side effects and measure how the drug moves through the body. The study also examined whether taking the drug with food affects how it's absorbed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New Zealand Clinical Research
Auckland, New Zealand
Conditions
Explore the condition pages connected to this study.